Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Mark L. Baum
AddedMar 31, 2024
UpdatedMay 31, 2026
Mark L. Baum

Mark L. Baum

Founder, Eton Pharmaceuticals

CrunchbaseLinkedIn

Mark L. Baum's Career

Eton Pharmaceuticals
Eton Pharmaceuticals

Deer Park, IL, US

Founder
Harrow
Harrow

Nashville, TN, US

Board Member· Board
Surface Pharmaceuticals
Surface Pharmaceuticals

Delaware, US

Founder
Surface Ophthalmics
Surface Ophthalmics

Pleasanton, CA, US

Co-Founder
Melt Pharmaceuticals
Melt Pharmaceuticals

Brentwood, TN, US

Board Member· Board
ImprimisRx
ImprimisRx

Carlsbad, CA, US

Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Mark L. Baum's Career

Eton Pharmaceuticals
Eton Pharmaceuticals
Public$38.1M282017Deer Park, IL, US
Founder

Leadership at Eton Pharmaceuticals

Charles CasamentoCharles CasamentoBoard Member
Sean BrynjelsenSean BrynjelsenCEO
Norbert RiedelNorbert RiedelBoard Member
Paul MaierPaul MaierBoard Member
Harrow
Harrow
Public$283.7M2172012Nashville, TN, US
Board Member· Board

Leadership at Harrow

Joe TonneJoe TonneCo-Founder
Teresa SparksTeresa SparksBoard Member
Mark L BaumMark L BaumCEO
Surface Pharmaceuticals
Surface Pharmaceuticals
Series A$46.8M82017Delaware, US
Founder

Leadership at Surface Pharmaceuticals

Perry SternbergPerry SternbergBoard Member
Dr Adrienne L GravesDr Adrienne L GravesBoard Member

Similar to Surface Pharmaceuticals

Surface OphthalmicsSurface OphthalmicsPleasanton, CA, USEye Drops, Therapeuticsest. 2016Surface OphthalmicsPleasanton, CA, US · est. 2016

Surface Ophthalmics, a biotech firm, innovates ocular disease treatments using patented Klarity delivery.

Series B · $40M5
TearClearTearClearCopley, OH, USPharmaceuticalsest. 2015TearClearCopley, OH, US · est. 2015

TearClear: A California-based pharmaceutical firm specializing in ocular surface medication delivery since 2015.

Series A · $52M12
MediPrint OphthalmicsMediPrint OphthalmicsSan Diego, CA, USPharmaceuticalsest. 2001MediPrint OphthalmicsSan Diego, CA, US · est. 2001

San Diego-based MediPrint Ophthalmics develops and commercializes proprietary ocular drugs to protect sight.

Series A · $7M7
TearSolutionsTearSolutionsCharlottesville, VA, USPharmaceuticalsest. 2013TearSolutionsCharlottesville, VA, US · est. 2013

TearSolutions: A pharmaceutical company specializing in dry eye medical solutions.

Pre-Seed · $21.1M11
Surface Ophthalmics
Surface Ophthalmics
Series B$40M52016Pleasanton, CA, US
Co-Founder

Leadership at Surface Ophthalmics

Kamran Hosseini, MD, PhDKamran Hosseini, MD, PhDCo-Founder & CEO
Melt Pharmaceuticals
Melt Pharmaceuticals
Series D$50M52019Brentwood, TN, US
Board Member· Board

Leadership at Melt Pharmaceuticals

John BerdahlJohn BerdahlCo-Founder
Larry DillahaLarry DillahaCEO

Similar to Melt Pharmaceuticals

Mirata PharmaceuticalsMirata PharmaceuticalsPlymouth Meeting, PA, USPain Relief, Pharmaceuticalsest. 2017Mirata PharmaceuticalsPlymouth Meeting, PA, US · est. 2017

Mirata Pharmaceuticals: Innovating powerful, opioid-based pain relief solutions for patients and physicians.

Series A · $11M5
Reset PharmaceuticalsReset PharmaceuticalsNew York City, NY, USPharmaceuticalsest. 2020Reset PharmaceuticalsNew York City, NY, US · est. 2020

Reset Pharma: A biotech firm specializing in the development of novel psychedelic treatments.

Series A · $11.1M37
PleoPharmaPleoPharmaPhoenixville, PA, USPharmaceuticalsest. 2020PleoPharmaPhoenixville, PA, US · est. 2020

PleoPharma: A high-ethics pharmaceutical firm dedicated to addressing significant medical needs.

Series A · $11.1M30
Amalgent TherapeuticsAmalgent TherapeuticsChapel Hill, NC, USPain Medicationsest. 2020Amalgent TherapeuticsChapel Hill, NC, US · est. 2020

Amalgent Therapeutics: Innovating safer, effective analgesia alternatives to opioids since 2020.

Angel · $450k2
ImprimisRx
ImprimisRx
Public$253k1231995Carlsbad, CA, US
Founder

Mark L. Baum's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Mark L. Baum

Mark HaydenMark HaydenFounder · Harrow SportsLuke FryerLuke FryerFounder · HarriJohn Henry HarrisJohn Henry HarrisCo-Founder · Electron TransportJosh ElkesJosh ElkesCo-Founder · HarbourMichael GilesMichael GilesFounder · Roboinvest